ReviewClinical pharmacology and therapeutics2021
Biomarker-Guided Individualization of Antibiotic Therapy.
Review in Clinical pharmacology and therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Procalcitonin to reduce exposure to antibiotics and individualise treatment in hospitalised old patients with pneumonia: a randomised study.BMC geriatrics · 2022Trial
- Article
- Cytokine-Driven Hyperinflammation in Long COVID: Mechanisms, Biomarkers, Complement Dysregulation, and Emerging Immunotherapies-A Narrative Review.Health science reports · 2026Article
- Taming the Cytokine Storm: Therapeutic Strategies for Post-Acute Sequelae of SARS-CoV-2 Infection.Health science reports · 2026Article
- Etiopathogenesis and Antibacterial Therapy Approach in Patients with Acute Obstructive Pyelonephritis-A Retrospective Study.Antibiotics (Basel, Switzerland) · 2026Article
- The association between unbound ceftriaxone area under the curve in the first 24 treatment hours and longitudinal C-reactive protein response in critically ill patients: an observational study.Intensive care medicine · 2026Article
- Duration Matters: Tailoring Antibiotic Therapy for Ventilator-Associated Pneumonia.Antibiotics (Basel, Switzerland) · 2026Review
- MicroRNA Profiling as a Novel Tool in the Diagnostics of Late-Onset Neonatal Sepsis: A Scoping Review.Children (Basel, Switzerland) · 2025Review
- Dose individualisation of antibiotics in critically ill patients with inflammation: A narrative review.British journal of clinical pharmacology · 2025Review
- Interplay between C-reactive protein responses and antibiotic prescribing in people with suspected infection.BMC infectious diseases · 2025Article
- Reprogramming the tumor microenvironment: synergistic mechanisms of antibody-drug conjugates and immune checkpoint inhibitors.Antibody therapeutics · 2025Review
- Polymerase Chain Reaction Chips for Biomarker Discovery and Validation in Drug Development.Micromachines · 2025Review
- Assessment of the Efficacy of Procalcitonin, C-Reactive Protein, and Albumin Levels-guided Antibiotics Use in Sepsis.Mediterranean journal of hematology and infectious diseases · 2025Article
- Healthcare Workers' Knowledge, Awareness, and Practices Regarding Antimicrobial Use, Resistance, and Stewardship in Saudi Arabia.Infection and drug resistance · 2025Article
- Plasma cell-free DNA Droplet Digital PCR provides rapid and efficient infectious microbiology diagnosis for febrile haematological patients.Frontiers in cellular and infection microbiology · 2025Article
- Mathematical model of the inflammatory response to acute and prolonged lipopolysaccharide exposure in humans.NPJ systems biology and applications · 2024Article
- The relation between inflammatory biomarkers and drug pharmacokinetics in the critically ill patients: a scoping review.Critical care (London, England) · 2024Article
- Machine Learning: A Potential Therapeutic Tool to Facilitate Neonatal Therapeutic Decision Making.Paediatric drugs · 2024Review
- Assessment value of interleukin-6, procalcitonin, and C-reactive protein early kinetics for initial antibiotic efficacy in patients with febrile neutropenia: A prospective study.Cancer medicine · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment failure of antibiotic therapy due to insufficient efficacy or occurrence of toxicity is a major clinical challenge, and is expected to become even more urgent with the global rise of antibiotic resistance. Strategies to optimize treatment in individual patients are therefore of crucial importance. Currently, therapeutic drug monitoring plays an important role in optimizing antibiotic exposure to reduce treatment failure and toxicity. Biomarker-based strategies may be a powerful tool to further quantify and monitor antibiotic treatment response, and reduce variation in treatment response between patients. Host response biomarkers, such as CRP, procalcitonin, IL-6, and presepsin, could potentially carry significant information to be utilized for treatment individualization. To achieve this, the complex interactions among immune system, pathogen, drug, and biomarker need to be better understood and characterized. The purpose of this tutorial is to discuss the use and evidence of currently available biomarker-based approaches to inform antibiotic treatment. To this end, we also included a discussion on how treatment response biomarker data from preclinical, healthy volunteer, and patient-based studies can be further characterized using pharmacometric and system pharmacology based modeling approaches. As an illustrative example of how such modeling strategies can be used, we describe a case study in which we quantitatively characterize procalcitonin dynamics in relation to antibiotic treatments in patients with sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.